Ensysce Biosciences Reports Third Quarter 2024 Financial Results
Portfolio Pulse from
Ensysce Biosciences reported its Q3 2024 financial results, highlighting a $14 million NIH grant and progress in clinical trials for its PF614-MPAR therapy. The company also submitted a Phase 3 protocol to the FDA.
November 12, 2024 | 9:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ensysce Biosciences reported Q3 2024 results, received a $14M NIH grant, and advanced its PF614-MPAR therapy with a Phase 3 FDA submission.
The $14M NIH grant and FDA submission for PF614-MPAR are significant milestones, indicating strong progress in Ensysce's clinical pipeline. These developments are likely to positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100